astrazeneca glp-1 AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. Results from the VISTA and SOLSTICE trials, published simultaneously AstraZeneca still 'playing to win'

Front Pharmacol (2021) 12:781856

Tamper evident: Do not use if outer seal is broken or missing

Takeaway While more research is needed, LDN shows promise in mental health due to its effects on endorphins, neuroinflammation, and opioid system modulation

According to scientific study based on animal test subjects, Epithalon has been shown to function with telomeres, which are areas of repeating DNA sequences that function to prevent gene degradation near the end of chromosomes

We need more targeted studies on low-dose and microdose effects, but the clinical signals are encouraging

doi: 10.1038/nn.4540, 150 van BloemendaalL.RgI